Keros Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| KROS | AVBP | GERN | AGMB | ZVRA | DSGN | |
|---|---|---|---|---|---|---|
| Market cap | 214.73M | 665.16M | 693.87M | 337.35M | 663.32M | 665.24M |
| P/E (TTM) | — | — | — | — | 9.2 | — |
| Forward P/E | -1.6 | -3.6 | 27.0 | -3.4 | 10.4 | -6.6 |
| Price/book | 0.8 | 1.8 | 3.1 | 2.7 | 4.1 | 3.0 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −30.80% | −28.97% | −14.68% | −53.24% | +1.89% | +57.86% |
| Today | 0.00% | +3.61% | +16.13% | 0.00% | +8.87% | +2.80% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All KROS news ›Keros Therapeutics (KROS) Projected to Post Quarterly Earnings on Wednesday
Posted by Kim Johansen on Nov 3rd, 2026 NASDAQ:KROS opened at $10.76 on Tuesday. Keros Therapeutics has a one year low of $9.69 and a one year high of $22.55. The stock has a market cap of $213.37 million, a PE ratio of -2.91 and a beta of…
Keros Therapeutics (NASDAQ:KROS) Stock Rating Lowered by Wall Street Zen
Keros Therapeutics (NASDAQ:KROS - Get Free Report) was downgraded by Wall Street Zen from a "sell" rating to a "strong sell" rating in a report released on Sunday, Wall Street Zen reports. Get Our Latest Stock Analysis on Keros…
More from 1 other outlet
Kalaris Therapeutics (NASDAQ:KLRS) Stock Rating Raised to “Hold” at Wall Street Zen
Posted by Tristan Rich on Nov 1st, 2026 Wall Street Zen upgraded shares of Kalaris Therapeutics (NASDAQ:KLRS – Free Report) from a sell rating to a hold rating in a research note published on Saturday,Wall Street Zen reports. Separately,…
More from 1 other outlet
BlackRock Portfolio Management Reports 9.1% Stake in Keros Therapeutics as of September 2026
BlackRock Portfolio Management LLC reported ownership of 1,813,870 shares of Keros Therapeutics common stock. Ownership percentage: Thi ... On October 27, 2026, BlackRock Portfolio Management LLC submitted an amended beneficial ownership…
Comparing Keros Therapeutics (NASDAQ:KROS) and Akebia Therapeutics (NASDAQ:AKBA)
Posted by Danessa Lincoln on Oct 24th, 2026 Keros Therapeutics (NASDAQ:KROS – Get Free Report) and Akebia Therapeutics (NASDAQ:AKBA – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will…
Keros Therapeutics Expects $20 Million Milestone Payment From Takeda
Keros Therapeutics said Tuesday it expects to receive a $20 million development milestone payment under the terms of its license agreement for elritercept with partner Takeda Pharmaceutical ,... Biotechnology & Medical Research Keros…
Keros Therapeutics Eyes 2027 DMD Data as Rinvatercept Takes Center Stage
Posted by Michael Walen on Oct 22nd, 2026 Seehra said Keros focuses on the TGF-β signaling pathway. The company partnered eleriscept with Takeda in 2024, and the program is now in three Phase III trials. Keros previously deprioritized and…
Reviewing Upstream Bio (NASDAQ:UPB) and Keros Therapeutics (NASDAQ:KROS)
Posted by Sarita Garza on Oct 12th, 2026 Keros Therapeutics (NASDAQ:KROS – Get Free Report) and Upstream Bio (NASDAQ:UPB – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- themarketsdaily.com5
- defenseworld.net2
- marketbeat.com2
- kalkinemedia.com1
- marketscreener.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 11 articles, not a forecast.